A phase I dose escalation trial of MAGE-A3- and HPV16-specific peptide immunomodulatory vaccines in patients with recurrent/metastatic (RM) squamous cell carcinoma of the head and neck (SCCHN)Dan P. Zandberg, Martin J. Edelman, Ming Tan et al.|Cancer Immunology Immunotherapy|2014Cited by 75
A phase I dose escalation trial of MAGE-A3 and HPV-16 specific peptide immunomodulatory vaccines in patients with recurrent/metastatic (RM) squamous cell carcinoma of the head and neck (SCCHN).Dan P. Zandberg, Martin J. Edelman, Sandra Rollins et al.|Journal of Clinical Oncology|2014Cited by 4
A Polymorphism in CD1e is associated with enhanced immune responses in African American Prostate Cancer Patients (46.40)Tonya J. Webb, Wenji Sun, Tiffany Dorsey et al.|The Journal of Immunology|2012Cited by 1
Effect of elevated expression of GST-π and p53 on prognosis in head and neck cancer patients treated with chemoradiotherapy but not radiotherapy alone: An analysis of RTOG trials 9003 and 9501K. J. Cullen, Lisa M. Schumaker, Nikolaos G. Nikitakis et al.|Journal of Clinical Oncology|2008Cited by 1